

Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT

NCT07442513

Status	RECRUITING
Phase	Phase 3
Sponsor	First Affiliated Hospital of Zhejiang University
Enrollment	404 participants

Key Eligibility Criteria

Inclusion (6)

- Age between 18 and 70 years (inclusive), regardless of gender;
- Patients diagnosed with a hematological disease requiring hematopoietic stem cell transplantation;
- Expected platelet count $\leq 10 \times 10^9/L$ persisting for 5 days or more;
- Normal coagulation function;
- Adequate organ function: Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 3 times the Upper Limit of Normal (ULN), Total Bilirubin $\leq 2 \times$ ULN; Serum Creatinine $\leq 2 \times$ ULN; Creatinine Clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula); Left Ventricular Ejection Fraction (LVEF) $\geq 50\%$ as measured by Echocardiography (ECHO);
- ... and 1 more (see full listing online)

Exclusion (11)

- Diagnosis of acute promyelocytic leukemia confirmed according to WHO diagnostic criteria;
- Pregnant or breastfeeding women, and women of childbearing potential unwilling to use effective contraception;
- Presence of active bleeding or infection;
- History of diagnosed primary immune thrombocytopenia or hemolytic uremic syndrome;
- Patients with known hereditary or acquired hemorrhagic disorders;
- ... and 6 more (see full listing online)

Locations (1 total)

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China